Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Hanel

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Oncotarget|February 1, 2018
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomasCarlos Murga-Zamalloa, Avery Polk, Walter Hanel, et al.
Hematological Oncology|May 10, 2024
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patientsKaitlin Annunzio, Subodh Bhatta, Walter Hanel, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 4, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexateZachary J Arnold, Jordan Lundberg, Tracy Wiczer, et al.
Cell Reports|December 21, 2022
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosisVijaya Bharti, Reese Watkins, Amrendra Kumar, et al.
Cancer Medicine|January 19, 2023
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agentsMuhammad Salman Faisal, Walter Hanel, Timothy Voorhees, et al.
Experimental Hematology & Oncology|September 22, 2023
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma modelsWing Keung Chan, Jessica Williams, Kinnari Sorathia, et al.
Blood Advances|February 26, 2025
Targeting the DNA damage response through TBL1X in mantle cell lymphomaBetsy Pray, Ethan James Baiocchi, Sydney Leon, et al.
Blood Advances|October 4, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort studyKaitlin Annunzio, Natalie S Grover, Rina Li Welkie, et al.
Leukemia|August 19, 2023
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphomaAnuvrat Sircar, Satishkumar Singh, Zijun Y Xu-Monette, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Oncotarget|February 1, 2018
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomasCarlos Murga-Zamalloa, Avery Polk, Walter Hanel, et al.
Hematological Oncology|May 10, 2024
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patientsKaitlin Annunzio, Subodh Bhatta, Walter Hanel, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 4, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexateZachary J Arnold, Jordan Lundberg, Tracy Wiczer, et al.
Cell Reports|December 21, 2022
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosisVijaya Bharti, Reese Watkins, Amrendra Kumar, et al.
Cancer Medicine|January 19, 2023
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agentsMuhammad Salman Faisal, Walter Hanel, Timothy Voorhees, et al.
Experimental Hematology & Oncology|September 22, 2023
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma modelsWing Keung Chan, Jessica Williams, Kinnari Sorathia, et al.
Blood Advances|February 26, 2025
Targeting the DNA damage response through TBL1X in mantle cell lymphomaBetsy Pray, Ethan James Baiocchi, Sydney Leon, et al.
Blood Advances|October 4, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort studyKaitlin Annunzio, Natalie S Grover, Rina Li Welkie, et al.
Leukemia|August 19, 2023
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphomaAnuvrat Sircar, Satishkumar Singh, Zijun Y Xu-Monette, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
Pageof 5